Revenue - Schedule of Disaggregated Revenues (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Royalties, license and other revenues	[1]	$ 310	$ 354	$ 567	$ 619
Total revenues under collaborative agreements		1,098	2,871	2,285	4,992
Total revenues		1,408	3,225	2,852	5,611
Upfront License Fees [Member]
Disaggregation of Revenue [Line Items]
Total revenues under collaborative agreements	[2]	$ 1,098	$ 2,871	$ 2,285	$ 4,992

[1] Included within royalties, license and other revenues recognized for the six months ended June 30, 2024 and 2023, was $30,000 and $87,000, respectively, that was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively.

[2] All of the upfront license fee revenue recognized each period was included within deferred revenue as contract liabilities at the beginning of the period. This revenue originated from the $50.0 million upfront payment under the Roche Agreement.